Beta-Cell Function After Near-Normalisation of Blood Glucose
NCT ID: NCT00612950
Last Updated: 2008-02-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
8 participants
INTERVENTIONAL
2006-10-31
2007-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Near Normalisation of BG Improves the Potentiating Effect of GLP-1
NCT00612625
Glucagon-Like Peptide-1 (GLP-1) Suppression of Alpha Cell Secretion in Type 2 Diabetes Mellitus (T2DM)
NCT00862589
Influence of Glucagon Inhibition in Relation to the Anti-Diabetic Effect of Glucagon-Like Peptide-1 (GLP-1) in Patients With Type 2 Diabetes Mellitus
NCT00655603
Effect of GLP-1 and GIP on Insulin Secretion in Type-1 Diabetes Mellitus
NCT00603031
The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes
NCT00732602
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GLP-1
glucagon-like peptide-1,
GLP-1:continuous infusion of ½ pmol/kg/min for a total time of 120 minutes.
GIP
glucose dependent insulinotropic polypeptide
continuous infusion of GIP (1½ pmol/kg/min) for 120 min.
saline
Saline
continuous infusion of Saline for 120 min
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
glucagon-like peptide-1,
GLP-1:continuous infusion of ½ pmol/kg/min for a total time of 120 minutes.
glucose dependent insulinotropic polypeptide
continuous infusion of GIP (1½ pmol/kg/min) for 120 min.
Saline
continuous infusion of Saline for 120 min
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Type 2 diabetes diagnosed after 30 years of age
* BMI \> 25
Exclusion Criteria
* Abnormal liver and kidney function
* Haemoglobin below the lower limit
* Macroalbuminuria
* Systemic disease
* Pregnancy
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hvidovre University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kettegaard Alle 30, 2650 Hvidovre
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Patricia V Højberg, MD, PHD
Role: PRINCIPAL_INVESTIGATOR
University Hospital Hvidovre
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dept. of Endocrinology, Hvidovre Hospital
Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hojberg PV, Vilsboll T, Rabol R, Knop FK, Bache M, Krarup T, Holst JJ, Madsbad S. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia. 2009 Feb;52(2):199-207. doi: 10.1007/s00125-008-1195-5. Epub 2008 Nov 27.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KA 03005
Identifier Type: -
Identifier Source: secondary_id
KA 03005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.